Avantect — Early Cancer Detection

Avantect Design System

Purple carries risk, teal carries action, lime carries the data. Everything on this site is built from the system's own tokens and components.

Brand in one screen

The hero treatment as it appears in product.

Pancreatic Cancer Test

When risk is elevated, clarity matters.

Avantect® is a blood-based test designed to detect signals of cancer at its earliest stages, supporting confident next-step decisions in elevated-risk care.

The clinical case

Stat rails and ring figures carry the survival argument.

3%
5-year relative survival for distant pancreatic cancer
1. SEER, 2024
44%
5-year relative survival when detected while localized
1. SEER, 2024
3%

Distant pancreatic cancer

44%

Localised pancreatic cancer

Purple Flags

Risk-factor cards with the system's three illustrated icons.

Family History

A first-degree relative diagnosed with pancreatic cancer.

Relative Risk: 4x – 9x8,9

Genetic Predisposition

Pathogenic variants such as BRCA1/2, ATM, or Lynch syndrome.

Relative Risk: 5x – 132x10

New-Onset Diabetes

Diabetes first diagnosed after age 50.

Relative Risk: 6x – 8x11

Ordering journey

Three steps on a dashed purple rail.

Step 01Request a collection kit
Step 02Collect and ship the sample
Step 03Results delivered in 14 days

Photography and product

Circle-cropped portraits and product shots on a quiet canvas.

A physician discussing results with a patient
The Avantect specimen collection kit box

Voice in practice

Hedged, cited, plain-spoken.

How to write it

Designed to inform, never to diagnose

Results read signal detected or signal not detected — never positive or negative.

  • Hedge words are required: signals, may, designed to.
  • Avantect® on first mention, plain Avantect after.
  • Cite every clinical figure inline.
  • No emoji, ever.

Purple is a signal, not a button

Elevated risk deserves a next step

Purple backs risk content. Teal remains the only action colour on the surface, so the way forward is always unambiguous.